Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system

References

• Abuasal BS, Lucas C, Peyton B, Alayoubi A, Nazzal S, Sylvester PW, Kaddoumi A. 2012. Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids. 47(5):461–469.
   PubMed Web of Science ®Google Scholar
• Adams J, Stein R. 1996. Novel inhibitors of the proteasome and their therapeutic use in inflammation. In: Bristol JA, editor. Annual reports in medicinal chemistry. Academic Press; p. 279–288.
   Google Scholar
• Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Kiziltepe T, Bilgicer B. 2014. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem. 57(12):5282–5292.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci. 89(4):429–442.
   PubMed Web of Science ®Google Scholar
• Balimane PV, Chong S, Morrison RA. 2000. Current methodologies used for evaluation of intestinal permeability and absorption. J Pharmacol Toxicol Methods. 44(1):301–312.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Qi J, Gogoi R, Wong J, Mitragotri S. 2016. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J Control Release. 238:176–185.
   PubMed Web of Science ®Google Scholar
• Bannunah AM, Vllasaliu D, Lord J, Stolnik S. 2014. Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm. 11(12):4363–4373.
   PubMed Web of Science ®Google Scholar
• Bromberg L. 2008. Polymeric micelles in oral chemotherapy. J Control Release. 128(2):99–112.
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Hamed Almurisi S, Ahmed Mahdi Dukhan A, Mandal UK, Sengupta P. 2016. Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view. Drug Deliv. 23(9):3639–3652.
   PubMed Web of Science ®Google Scholar
• Cherniakov I, Domb AJ, Hoffman A. 2015. Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects. Expert Opin Drug Deliv. 12(7):1121–1133.
   PubMed Web of Science ®Google Scholar
• Constantinides PP, Wasan KM. 2007. Lipid formulation strategies for enhancing intestinal transport and absorption of P‐glycoprotein (P‐gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 96(2):235–248.
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm. 278(1):119–131.
   PubMedGoogle Scholar
• Crawford LJ, Walker B, Irvine AE. 2011. Proteasome inhibitors in cancer therapy. J Cell Commun Signal. 5(2):101–110.
   PubMed Web of Science ®Google Scholar
• Dahan A, Amidon GL. 2009. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 6(1):19–28.
   PubMed Web of Science ®Google Scholar
• Dahan A, Lennernäs H, Amidon G L. 2012. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 9(6):1847–1851.
   PubMedGoogle Scholar
• El-Laithy HM, Basalious EB, El-Hoseiny BM, Adel MM. 2015. Novel self-nanoemulsifying self-nanosuspension (SNESNS) for enhancing oral bioavailability of diacerein: simultaneous portal blood absorption and lymphatic delivery. Int J Pharm. 490(1-2):146–154.
   PubMed Web of Science ®Google Scholar
• Fagerholm U, Johansson M, Lennernäs H. 1996. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 13(9):1336–1342.
   PubMed Web of Science ®Google Scholar
• Foran E, Kwon DY, Nofziger JH, Arnold ES, Hall MD, Fischbeck KH, Burnett BG. 2016. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 88:118–124.
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 58(3):173–182.
   PubMed Web of Science ®Google Scholar
• Hamid KA, Katsumi H, Sakane T, Yamamoto A. 2009. The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats. Int J Pharm. 379(1):100–108.
   PubMedGoogle Scholar
• Honary S, Zahir F. 2013. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop J Pharm Res. 12(2):265–273.
   Google Scholar
• Hong E-P, Kim J-Y, Kim S-H, Hwang K-M, Park C-W, Lee H-J, Kim D-W, Weon K-Y, Jeong SY, Park E-S. 2016. Formulation and evaluation of a self-microemulsifying drug delivery system containing bortezomib. Chem Pharm Bull. 64(8):1108–1117.
   PubMed Web of Science ®Google Scholar
• Koga K, Ohyashiki T, Murakami M, Kawashima S. 2000. Modification of ceftibuten transport by the addition of non-ionic surfactants. Eur J Pharm Biopharm. 49(1):17–25.
   PubMed Web of Science ®Google Scholar
• Kohli K, Chopra S, Dhar D, Arora S, Khar RK. 2010. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov Today. 15(21-22):958–965.
   PubMed Web of Science ®Google Scholar
• Leveque D, Carvalho MCM, Maloisel F. 2007. Review. Clinical pharmacokinetics of bortezomib. In Vivo. 21(2):273–278.
   PubMed Web of Science ®Google Scholar
• Lü S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J. 2010. The effects of proteasome inhibitor bortezomib on a P‐gp positive leukemia cell line K562/A02. Int J Lab Hematol. 32(1p1):e123.
   PubMedGoogle Scholar
• Mahmoudian M, Valizadeh H, Zakeri-Milani P. 2018. Bortezomib–loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation. Drug Dev Ind Pharm. 44(10):1598–1605.
   PubMed Web of Science ®Google Scholar
• Mahmoudian M, Zakeri-Milani P, Valizadeh H. 2018. Investigating intestinal permeability of bortezomib using a validated HPLC-UV method. Drug Res. 69(3):130–135.
   Web of Science ®Google Scholar
• Mallikarjun C, Kok K, Yusrida D, Muthanna A, Ghassan Z, Mohammed J. 2011. Intestinal permeability studies of sulpiride incorporated into self-micro emulsifying drug delivery system (SMEDDS). Pak J Pharm Sci. 24:113–121.
   PubMed Web of Science ®Google Scholar
• Marinaro WA, Schieber LJ, Munson EJ, Day VW, Stella VJ. 2012. Properties of a model aryl boronic acid and its boroxine. J Pharm Sci. 101(9):3190–3198.
   PubMed Web of Science ®Google Scholar
• Mazzaferro S, Bouchemal K, Ponchel G. 2013. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 18(1-2):25–34.
   PubMed Web of Science ®Google Scholar
• Mei L, Zhang Z, Zhao L, Huang L, Yang X-L, Tang J, Feng S-S. 2013. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 65(6):880–890.
   PubMed Web of Science ®Google Scholar
• Nix D, Pien C, Newman R, Felix E, Adams J, Elliott P. 2001. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc Am Soc Clin Oncol. 20:86a.
   Google Scholar
• O’Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS. 2013. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 71(5):1357–1368.
   PubMed Web of Science ®Google Scholar
• Olfert ED, Cross BM, McWilliam AA. 1993. Guide to the care and use of experimental animals, Vol. 1. Ontario, Canada: Canadian Council on Animal Care Ottawa.
   Google Scholar
• O'neill V, Twelves C. 2002. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 87(9):933.
   PubMed Web of Science ®Google Scholar
• Dou PQ, Zonder JA. 2014. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 14(6):517–536.
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJ. 2008. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 60(6):625–637.
   PubMed Web of Science ®Google Scholar
• Reddy RN, Shariff A. 2013. Solid lipid nanoparticles: an advanced drug delivery system. Int J Pharm Sci Res. 4(1):161.
   Google Scholar
• Reece D E, Sullivan D, Lonial S, Mohrbacher A F, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan W J, et al. 2011. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 67(1):57–67.
   PubMed Web of Science ®Google Scholar
• Shahbazi M-A, Santos HA. 2013. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metabol. 14(1):28–56.
   PubMed Web of Science ®Google Scholar
• Singh G, Pai RS. 2015. Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv. 22(4):522–530.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. 2015. Proteasome inhibitors. Biochem Pharmacol. 96(1):1–9.
   PubMed Web of Science ®Google Scholar
• Varma M, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, Thomas N, Pillai O, Sharma P, Gandhi R, et al. 2004. Biopharmaceutic classification system: a scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab. 5(5):375–388.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45(12):2615–2623.
   PubMed Web of Science ®Google Scholar
• Voorhees P M, Dees E C, O'Neil B, Orlowski R Z. 2003. The proteasome as a target for cancer therapy. Clin Cancer Res. 9(17):6316–6325.
   PubMed Web of Science ®Google Scholar
• Wu K, Cheng R, Zhang J, Meng F, Deng C, Zhong Z. 2017. Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer. J Mater Chem B. 5(28):5658–5667.
   Web of Science ®Google Scholar
• Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. 2009. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm. 73(1):102–106.
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, Barzegar-Jalali M. 2007. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 10(3):368–379.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yao M, Morrison RA, Chong S. 2003. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res. 26(9):768–772.
   PubMed Web of Science ®Google Scholar